BACKGROUND AND AIMS: 1.4-Dihydroxy-2-naphthoic acid (DHNA), a bifidogenic growth stimulator from Propionibacterium freudenreichii, is thought to have a beneficial effect as a prebiotic; however, its in vivo effect on intestinal inflammation remains unknown. The aim of this study was to determine whether oral administration of DHNA can ameliorate dextran sodium sulphate (DSS) induced colitis and to determine the possible underlying mechanisms. METHOD: Colitis was induced in mice by treatment with 2.0% DSS for seven days. DHNA (0.6 or 2.0 mg/kg) was given in drinking water prior to (preventive study) or after (therapeutic study) DSS administration. Colonic damage was histologically scored, and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) expression and beta7 positive cell infiltration were determined by immunohistochemistry. mRNA levels of proinflammatory cytokines (interleukin (IL)-1beta, IL-6 and tumour necrosis factor alpha (TNF-alpha)) were determined by quantitative real time polymerase chain reaction. In addition, bacterial flora in the caecum, concentrations of short chain acids, and luminal pH were examined. RESULTS: DHNA improved survival rate and histological damage score in mice administered DSS in both the preventive and therapeutic studies. DHNA significantly attenuated the enhanced expression of MAdCAM-1, the increased beta7 positive cell number, and the increased mRNA levels of IL-1beta, IL-6, and TNF-alpha in DSS treated colon. In addition, the decreased number of Lactobacillus and Enterobacteriaceae induced by DSS was recovered by DHNA. Preventive effects on decrease in butyrate concentration and decrease in pH level in mice administered DSS were also observed in the DHNA preventive study. CONCLUSION: DHNA, a novel type of prebiotic, attenuates colonic inflammation not only by balancing intestinal bacterial flora but also by suppressing lymphocyte infiltration through reduction of MAdCAM-1.
BACKGROUND AND AIMS: 1.4-Dihydroxy-2-naphthoic acid (DHNA), a bifidogenic growth stimulator from Propionibacterium freudenreichii, is thought to have a beneficial effect as a prebiotic; however, its in vivo effect on intestinal inflammation remains unknown. The aim of this study was to determine whether oral administration of DHNA can ameliorate dextran sodium sulphate (DSS) induced colitis and to determine the possible underlying mechanisms. METHOD:Colitis was induced in mice by treatment with 2.0% DSS for seven days. DHNA (0.6 or 2.0 mg/kg) was given in drinking water prior to (preventive study) or after (therapeutic study) DSS administration. Colonic damage was histologically scored, and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) expression and beta7 positive cell infiltration were determined by immunohistochemistry. mRNA levels of proinflammatory cytokines (interleukin (IL)-1beta, IL-6 and tumour necrosis factor alpha (TNF-alpha)) were determined by quantitative real time polymerase chain reaction. In addition, bacterial flora in the caecum, concentrations of short chain acids, and luminal pH were examined. RESULTS:DHNA improved survival rate and histological damage score in mice administered DSS in both the preventive and therapeutic studies. DHNA significantly attenuated the enhanced expression of MAdCAM-1, the increased beta7 positive cell number, and the increased mRNA levels of IL-1beta, IL-6, and TNF-alpha in DSS treated colon. In addition, the decreased number of Lactobacillus and Enterobacteriaceae induced by DSS was recovered by DHNA. Preventive effects on decrease in butyrate concentration and decrease in pH level in mice administered DSS were also observed in the DHNA preventive study. CONCLUSION:DHNA, a novel type of prebiotic, attenuates colonic inflammation not only by balancing intestinal bacterial flora but also by suppressing lymphocyte infiltration through reduction of MAdCAM-1.
Authors: H C Rath; H H Herfarth; J S Ikeda; W B Grenther; T E Hamm; E Balish; J D Taurog; R E Hammer; K H Wilson; R B Sartor Journal: J Clin Invest Date: 1996-08-15 Impact factor: 14.808
Authors: F Fernández-Bañares; J Hinojosa; J L Sánchez-Lombraña; E Navarro; J F Martínez-Salmerón; A García-Pugés; F González-Huix; J Riera; V González-Lara; F Domínguez-Abascal; J J Giné; J Moles; F Gomollón; M A Gassull Journal: Am J Gastroenterol Date: 1999-02 Impact factor: 10.864
Authors: R K Sellon; S Tonkonogy; M Schultz; L A Dieleman; W Grenther; E Balish; D M Rennick; R B Sartor Journal: Infect Immun Date: 1998-11 Impact factor: 3.441
Authors: Y Okada; Y Tsuzuki; H Sato; K Narimatsu; R Hokari; C Kurihara; C Watanabe; K Tomita; S Komoto; A Kawaguchi; S Nagao; S Miura Journal: Clin Exp Immunol Date: 2013-12 Impact factor: 4.330
Authors: M Kverka; Z Zakostelska; K Klimesova; D Sokol; T Hudcovic; T Hrncir; P Rossmann; J Mrazek; J Kopecny; E F Verdu; H Tlaskalova-Hogenova Journal: Clin Exp Immunol Date: 2010-11-19 Impact factor: 4.330
Authors: Pingwei Zhao; Haleli Sharir; Ankur Kapur; Alan Cowan; Ellen B Geller; Martin W Adler; Herbert H Seltzman; Patricia H Reggio; Susanne Heynen-Genel; Michelle Sauer; Thomas D Y Chung; Yushi Bai; Wei Chen; Marc G Caron; Larry S Barak; Mary E Abood Journal: Mol Pharmacol Date: 2010-07-22 Impact factor: 4.436
Authors: Hans B Smith; Tin Lok Li; Man Kit Liao; Grischa Y Chen; Zhihong Guo; John-Demian Sauer Journal: Infect Immun Date: 2021-04-16 Impact factor: 3.441
Authors: M Matsubara; E Yamachika; H Tsujigiwa; N Mizukawa; T Ueno; J Murakami; N Ishida; Y Kaneda; N Shirasu; S Takagi Journal: Osteoporos Int Date: 2009-10-08 Impact factor: 4.507